Breaking News Instant updates and real-time market news.

LPCN

Lipocine

$4.02

0.15 (3.88%)

16:04
06/19/17
06/19
16:04
06/19/17
16:04

Lipocine says LPCN 1021 achieved primary endpoints in dosing studies

Lipocine announced results from both the Dosing Validation and the Dosing Flexibility studies evaluating efficacy and tolerability of LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. The results from these studies confirm the validity of a fixed dose approach without the need for dose titration to orally administering LPCN 1021. LPCN 1021 successfully met the FDA primary efficacy guidelines in the DV study where 81% of the subjects achieved average testosterone levels within the normal range with a lower bound confidence interval of 72%. The DF study restored 70% of the subjects' average testosterone levels within the normal range confirming that twice daily dosing is the appropriate dosing regimen for LPCN 1021 and will be the basis for resubmission. The adverse event profile of LPCN 1021 in both the DV and DF studies was consistent with the previously conducted 52-week Phase 3 Study of Androgen Replacement clinical trial. All drug related adverse events were either mild or moderate in intensity and none were severe, the company said. "We are pleased with the confirmation of LPCN 1021 efficacy, especially with a more practical patient and physician preferred "no titration" dosing regimen. We believe the results should address the label-related deficiency cited by the FDA in our NDA submission. We consider LPCN 1021 to be a differentiated TRT option for treating hypogonadism in men with the potential to both improve patient compliance and eliminate the risk of testosterone transference. We look forward to resubmitting the NDA in the third quarter of 2017," said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine.

  • 19

    Jun

LPCN Lipocine
$4.02

0.15 (3.88%)

10/07/16
HCWC
10/07/16
INITIATION
Target $25
HCWC
Buy
Lipocine initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Lipocine with a Buy rating and $25 price target.
10/11/16
ADAM
10/11/16
NO CHANGE
Target $15
ADAM
Buy
Lipocine price target raised to $15 from $6 at Canaccord
Canaccord analyst John Newman raised his price target on Lipocine to $15 from $6 as he believes its oral testosterone product has better safety and convenience versus currently marketed gels and injectables. The analyst sees rapid market share gains and a 20% market share by 2024. Newman reiterated his Buy rating on Lipocine shares.
12/20/16
ADAM
12/20/16
INITIATION
Target $15
ADAM
Buy
Lipocine assumed with a Buy at Canaccord
Canaccord analyst Dewey Steadman assumed Lipocine with Buy and $15 price target citing its status as one of the leading companies developing oral testosterone replacement therapies to treat hypogonadism.
02/21/17
ROTH
02/21/17
NO CHANGE
Target $38
ROTH
Buy
Lipocine price target raised to $38 from $30 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Lipocine to $38 from $30 following clarity on LPCN-1107's pivotal trial design. The analyst reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

FEYE

FireEye

11:45
06/27/17
06/27
11:45
06/27/17
11:45
Options
FireEye call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

11:45
06/27/17
06/27
11:45
06/27/17
11:45
General news
Treasury's $40 B 4-week bill sale was poorly subscribed »

Treasury's $40 B…

BT

BT Group

$18.68

0.06 (0.32%)

11:42
06/27/17
06/27
11:42
06/27/17
11:42
Upgrade
BT Group rating change  »

BT Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
06/27/17
06/27
11:35
06/27/17
11:35
General news
Treasury Option Action: a round of call buying in the belly »

Treasury Option Action: a…

OSUR

OraSure

$15.72

0.17 (1.09%)

11:31
06/27/17
06/27
11:31
06/27/17
11:31
Recommendations
OraSure analyst commentary  »

OraSure price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

XLF

Financial Select Sector

$24.19

0.17 (0.71%)

11:30
06/27/17
06/27
11:30
06/27/17
11:30
Options
SPDR Financial calls outpace puts nearly 25:1 »

SPDR Financial calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KITE

Kite Pharma

$100.43

-0.23 (-0.23%)

11:25
06/27/17
06/27
11:25
06/27/17
11:25
Options
Kite Pharma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

ANY

Sphere 3D

$0.20

0.0275 (16.08%)

11:25
06/27/17
06/27
11:25
06/27/17
11:25
Conference/Events
Sphere 3D to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MRK

Merck

$66.14

0.215 (0.33%)

11:20
06/27/17
06/27
11:20
06/27/17
11:20
Periodicals
Merck confirms computer network 'compromised' by global hack »

Merck stated in a series…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

11:20
06/27/17
06/27
11:20
06/27/17
11:20
General news
Fed's Harker still backs another rate hike this year »

Fed's Harker still…

BLK

BlackRock

$425.20

0.51 (0.12%)

11:17
06/27/17
06/27
11:17
06/27/17
11:17
Hot Stocks
BlackRock to acquire Cachematrix »

BlackRock has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
06/27/17
06/27
11:17
06/27/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
06/27/17
06/27
11:16
06/27/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
06/27/17
06/27
11:15
06/27/17
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

PSX

Phillips 66

$80.96

0.72 (0.90%)

, CVX

Chevron

$104.76

0.62 (0.60%)

11:11
06/27/17
06/27
11:11
06/27/17
11:11
Hot Stocks
Chevron Phillips Chemical names Mark Lashier CEO »

Chevron Phillips Chemical…

PSX

Phillips 66

$80.96

0.72 (0.90%)

CVX

Chevron

$104.76

0.62 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

11:10
06/27/17
06/27
11:10
06/27/17
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

ALDR

Alder Biopharmaceuticals

$18.70

-1 (-5.08%)

11:03
06/27/17
06/27
11:03
06/27/17
11:03
Recommendations
Alder Biopharmaceuticals analyst commentary  »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

AA

Alcoa

$32.33

1.15 (3.69%)

11:00
06/27/17
06/27
11:00
06/27/17
11:00
Options
Alcoa attracts call buying »

Alcoa attracts call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
06/27/17
06/27
11:00
06/27/17
11:00
General news
FX Action: USD-CAD »

FX Action: USD-CAD fell…

11:00
06/27/17
06/27
11:00
06/27/17
11:00
General news
Breaking General news story  »

Philadelphia Federal…

HCC

Warrior Met Coal

$15.88

-0.31 (-1.91%)

10:58
06/27/17
06/27
10:58
06/27/17
10:58
Downgrade
Warrior Met Coal rating change  »

Follow-up: Warrior Met…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BV

Bazaarvoice

$4.80

-0.1 (-2.04%)

10:56
06/27/17
06/27
10:56
06/27/17
10:56
Conference/Events
Bazaarvoice management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

CBI

CB&I

$16.50

2.1 (14.58%)

, TOSBF

Toshiba, also use TOSYY

$2.69

0.03 (1.13%)

10:55
06/27/17
06/27
10:55
06/27/17
10:55
Periodicals
Court rules for Chicago Bridge in Westinghouse case, Reuters says »

The Delaware Supreme…

CBI

CB&I

$16.50

2.1 (14.58%)

TOSBF

Toshiba, also use TOSYY

$2.69

0.03 (1.13%)

TOSYY

Toshiba, also use TOSBF

$15.91

-0.065 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
06/27/17
06/27
10:55
06/27/17
10:55
Conference/Events
Federal Reserve Bank of Philadelphia President speaks on economic outlook »

Philadelphia Federal…

LTRX

Lantronix

$2.37

-0.08 (-3.27%)

10:54
06/27/17
06/27
10:54
06/27/17
10:54
Conference/Events
Lantronix management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.